- Home
- EEX vs MLYS Comparison
EEX vs MLYS Comparison
Compare EEX & MLYS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EEX
- MLYS
- Stock Information
- Founded
- EEX 2013
- MLYS 2019
- Country
- EEX United States
- MLYS United States
- Employees
- EEX N/A
- MLYS N/A
- Industry
- EEX Advertising
- MLYS Biotechnology: Pharmaceutical Preparations
- Sector
- EEX Consumer Discretionary
- MLYS Health Care
- Exchange
- EEX Nasdaq
- MLYS Nasdaq
- Market Cap
- EEX 749.0M
- MLYS 893.0M
- IPO Year
- EEX 2017
- MLYS 2023
- Fundamental
- Price
- EEX $3.66
- MLYS $13.53
- Analyst Decision
- EEX Strong Buy
- MLYS Strong Buy
- Analyst Count
- EEX 2
- MLYS 3
- Target Price
- EEX $7.90
- MLYS $33.00
- AVG Volume (30 Days)
- EEX 136.2K
- MLYS 1.2M
- Earning Date
- EEX 05-06-2025
- MLYS 05-08-2025
- Dividend Yield
- EEX 1.20%
- MLYS N/A
- EPS Growth
- EEX N/A
- MLYS N/A
- EPS
- EEX N/A
- MLYS N/A
- Revenue
- EEX $398,800,000.00
- MLYS N/A
- Revenue This Year
- EEX $14.47
- MLYS N/A
- Revenue Next Year
- EEX $6.42
- MLYS N/A
- P/E Ratio
- EEX N/A
- MLYS N/A
- Revenue Growth
- EEX 4.18
- MLYS N/A
- 52 Week Low
- EEX $3.22
- MLYS $8.24
- 52 Week High
- EEX $6.74
- MLYS $18.38
- Technical
- Relative Strength Index (RSI)
- EEX 46.77
- MLYS 51.00
- Support Level
- EEX $3.44
- MLYS $12.77
- Resistance Level
- EEX $3.67
- MLYS $14.83
- Average True Range (ATR)
- EEX 0.21
- MLYS 1.17
- MACD
- EEX 0.02
- MLYS -0.09
- Stochastic Oscillator
- EEX 62.24
- MLYS 70.39
About EEX Emerald Holding Inc.
Emerald Holding Inc is an operator of B2B trade shows in the United States. The company is engaged in three complementary business lines; Connections division consists of a collection of B2B trade show franchises and other live events that provide exhibitors opportunities to engage with buyers and expand their brand's awareness in their industry, Content division consists of B2B print publications and digital media products that complement existing trade show properties, and the Commerce division which offers software-as-a-service technology that enables year-round B2B buying and selling through Elastic Suite and Bulletin platforms for use by its customers. Majority of the revenue for the company is generated from its Connections segment.
About MLYS Mineralys Therapeutics Inc.
Mineralys Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing medicines to target diseases driven by abnormally elevated aldosterone. The company's product candidate, lorundrostat, is a proprietary, orally administered, selective aldosterone synthase inhibitor, that is initially developed for the treatment of patients with uncontrolled hypertension, defined as individuals who are unable to achieve BP of below 130/80 mmHg despite taking two or more lines of antihypertensive medication or resistant hypertension, typically including a diuretic.